---
layout: default
title: Carteolol Hcl
parent: 僅模型預測 (L5)
nav_order: 132
evidence_level: L5
indication_count: 0
---

# Carteolol Hcl
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# CARTEOLOL HCL: Drug Repurposing Assessment — Insufficient Evidence Pack for Full Evaluation

## One-Sentence Summary

Carteolol HCL is a non-selective beta-adrenergic blocker, principally used as an ophthalmic preparation for the reduction of elevated intraocular pressure in glaucoma and ocular hypertension, and systemically for hypertension.
The TxGNN Evidence Pack submitted for this candidate contains **no predicted indications**, as the `predicted_indications` array is empty.
Without a target repurposing indication, a full mechanistic and clinical evaluation **cannot be completed at this stage**.

---

## Quick Overview

| Item | Content |
|------|---------|
| Drug Name (INN) | Carteolol HCL |
| Known Drug Class | Non-selective beta-adrenergic blocker with intrinsic sympathomimetic activity (ISA) |
| Predicted New Indication | None — no TxGNN prediction available in this Evidence Pack |
| TxGNN Prediction Score | Not available |
| Evidence Level | L5 (model prediction only — but no indication has even been predicted) |
| UK Market Status | Not marketed |
| Number of UK Marketing Authorisations | 0 |
| Recommended Decision | **Hold** |

---

## Why This Assessment Cannot Proceed

The Evidence Pack for Carteolol HCL contains two structural deficiencies that prevent a substantive drug repurposing evaluation:

**1. No TxGNN prediction available.** The `predicted_indications` field is an empty array. The TxGNN model has not returned a ranked candidate indication for this drug under the submitted query. This may indicate that Carteolol HCL was not matched to a DrugBank node in the knowledge graph (DrugBank ID is `null`), which would prevent the model from traversing drug–disease edges. Without a predicted target indication, there is no repurposing hypothesis to evaluate.

**2. No UK regulatory footprint.** Carteolol HCL holds zero MHRA marketing authorisations and is classified as not marketed in the United Kingdom. While absence of UK authorisation does not preclude a repurposing investigation, it means there is no extant SmPC, UK prescribing information, or NICE appraisal to draw safety and dosing guidance from.

Based on general pharmacological knowledge, Carteolol HCL is a beta-adrenoceptor antagonist with partial agonist activity. Its established clinical roles include reduction of intraocular pressure (ophthalmic route) and management of hypertension and angina (systemic route). Any future repurposing hypothesis — for example, in cardiovascular disease, arrhythmia, or portal hypertension — would need to be grounded in a successful DrugBank mapping and a valid TxGNN graph traversal before proceeding to evidence synthesis.

---

## Safety Considerations

All safety fields in this Evidence Pack are flagged as data gaps. No key warnings, contraindications, or drug–drug interaction data were returned.

> Please refer to the SmPC and BNF for safety information once a UK-authorised equivalent is identified. Report suspected adverse reactions via the Yellow Card Scheme.

For reference, beta-blockers as a class carry well-documented class-level concerns including bronchospasm in asthmatic patients, masking of hypoglycaemic symptoms, bradycardia, and rebound hypertension on abrupt withdrawal — these should be addressed formally once a full SmPC is retrieved.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack for Carteolol HCL is fundamentally incomplete: it contains no TxGNN-predicted indication, no DrugBank ID, no safety data, and no UK regulatory information, making it impossible to perform even a preliminary repurposing feasibility assessment.

**To proceed, the following is needed:**

1. **Resolve DrugBank mapping** — Carteolol HCL must be linked to a valid DrugBank ID (likely DB01136 for Carteolol). The failed mapping is likely the root cause of the absent TxGNN prediction. Re-run the DrugBank mapper using the INN "carteolol" (without the HCL salt suffix) or the CAS number 51781-21-6.

2. **Re-run TxGNN prediction** — Once the DrugBank node is confirmed, resubmit the candidate through the KG and DL prediction pipeline to obtain ranked repurposing indications with confidence scores.

3. **Retrieve mechanism of action data** — Query the DrugBank API for Carteolol's MOA, pharmacodynamics, and target proteins (beta-1 and beta-2 adrenoceptors) to support mechanistic plausibility analysis.

4. **Obtain safety data** — Retrieve the full SmPC from a jurisdiction where Carteolol is marketed (e.g., Japan: Mikelan®; France: Carteol®) or consult the EMA product database. Parse key warnings, contraindications, and drug interaction profiles.

5. **Assess UK licensing pathway** — Confirm whether any Article 10 (generic) or bibliographic application route is feasible for UK market entry, should a repurposing indication be substantiated.

6. **Re-submit a complete Evidence Pack** — Once steps 1–5 are complete, re-run the full pipeline to generate a v5-compliant Evidence Pack with populated `predicted_indications`, `drugbank_id`, and `safety` fields before commissioning a clinical evaluation report.

---

*This report is generated for research purposes only and does not constitute medical advice. All drug repurposing candidates require clinical validation before any therapeutic application. Adverse reactions should be reported via the MHRA Yellow Card Scheme.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

